+++
title = "Henry's Clinical diagnosis and management by McPherson and Pincus in 2016"
author = ["Cameron Smith"]
lastmod = 2020-09-24T01:10:48-04:00
slug = "Henry's_Clinical_diagnosis_and_management_by_McPherson_and_Pincus_in_2016"
draft = false
+++

## Part 4: Hematology and transfusion medicine {#part-4-hematology-and-transfusion-medicine}


### hematopathology (510-734 = 224) {#hematopathology--510-734-224}

<!--list-separator-->

-  30. Basic examination of blood and bone marrow (510-539)

    <!--list-separator-->

    -  Hematology principles and procedures

        <!--list-separator-->

        -  Hemoglobin

        <!--list-separator-->

        -  Hematocrit (packed cell volume)

        <!--list-separator-->

        -  Erythrocyte indices

        <!--list-separator-->

        -  Manual blood cell counts

        <!--list-separator-->

        -  Instrument technology

    <!--list-separator-->

    -  Blood film examination

        <!--list-separator-->

        -  Examination of wet preparations

        <!--list-separator-->

        -  Making and staining blood films

        <!--list-separator-->

        -  Erythrocytes

        <!--list-separator-->

        -  Leukocytes on peripheral blood smear examination

        <!--list-separator-->

        -  Platelets on peripheral blood smear examination

        <!--list-separator-->

        -  Erythrocytes

<!--list-separator-->

-  31. Hematopoiesis (540-558)

<!--list-separator-->

-  32. Erythrocytic disorders (559-605)

    <!--list-separator-->

    -  32.1 Anemias

        <!--list-separator-->

        -  General manifestations

        <!--list-separator-->

        -  Impaired production--Iron deficiency anemia

            <!--list-separator-->

            -  Iron metabolism

            <!--list-separator-->

            -  Iron deficiency anemia

                <!--list-separator-->

                -  Clinical features

                <!--list-separator-->

                -  Laboratory features

                    <!--list-separator-->

                    -  blood

                    <!--list-separator-->

                    -  marrow

                    <!--list-separator-->

                    -  serum iron

                    <!--list-separator-->

                    -  serum iron-binding capacity

                    <!--list-separator-->

                    -  percent saturation of TIBC

                    <!--list-separator-->

                    -  serum ferritin

                    <!--list-separator-->

                    -  erythrocyte porphyrins

                    <!--list-separator-->

                    -  serum transferrin receptors

                    <!--list-separator-->

                    -  serum transferrin receptors

                    <!--list-separator-->

                    -  serum transferrin receptor-to-serum ferritin ratio

                    <!--list-separator-->

                    -  reticulocyte hemoglobin content

                    <!--list-separator-->

                    -  hepcidin level

                <!--list-separator-->

                -  Differential diagnosis

                <!--list-separator-->

                -  Management

            <!--list-separator-->

            -  Iron-refractory iron deficiency anemia (IRIDA)

        <!--list-separator-->

        -  Impaired production--Megaloblastic anemia

            <!--list-separator-->

            -  Macrocytosis with normoblastic marrow

            <!--list-separator-->

            -  Megaloblastic anemia

                <!--list-separator-->

                -  blood

                <!--list-separator-->

                -  marrow

                <!--list-separator-->

                -  erythrokinetics

            <!--list-separator-->

            -  Cobalamin (Vitamin B12) metabolism

            <!--list-separator-->

            -  Cobalamin deficiency

                <!--list-separator-->

                -  Inadequate intake

                <!--list-separator-->

                -  Defective production of intrinsic factor

            <!--list-separator-->

            -  Pernicious anemia

                <!--list-separator-->

                -  clinical features

                <!--list-separator-->

                -  gastric findings

                <!--list-separator-->

                -  immune abnormalities

                <!--list-separator-->

                -  pernicious anemia in children

                <!--list-separator-->

                -  gastrectomy

                <!--list-separator-->

                -  defective absorption of cobalamin

                    <!--list-separator-->

                    -  malabsorption syndromes

                    <!--list-separator-->

                    -  lack of availability

                <!--list-separator-->

                -  diagnosis of cobalamin deficiency

                    <!--list-separator-->

                    -  therapeutic trial

                    <!--list-separator-->

                    -  serum cobalamin assay

                    <!--list-separator-->

                    -  methylmalonic acid and homocysteine assays

                    <!--list-separator-->

                    -  deoxyuridine suppression test

                <!--list-separator-->

                -  detecting the cause of cobalamin deficiency

            <!--list-separator-->

            -  Folic acid metabolism

                <!--list-separator-->

                -  The folate-cobalamin relationship

            <!--list-separator-->

            -  Folic acid deficiency

                <!--list-separator-->

                -  Inadequate intake of folate

                    <!--list-separator-->

                    -  Evolution of laboratory abnormalities

                    <!--list-separator-->

                    -  Nutritional folate defiency

                    <!--list-separator-->

                    -  Liver disease

                <!--list-separator-->

                -  Defective absorption of folate

                <!--list-separator-->

                -  Increased requirement for folate

                <!--list-separator-->

                -  Inadequate utilization of folate

                <!--list-separator-->

                -  Diagnosis of folate deficiency

                    <!--list-separator-->

                    -  Serum and red cell folate

                    <!--list-separator-->

                    -  Urinary formiminoglutamic acid (FIGLU)

                    <!--list-separator-->

                    -  Deoxyuridine suppression test

                    <!--list-separator-->

                    -  Plasma homocysteine assay

                <!--list-separator-->

                -  Acute megaloblastic anemia

            <!--list-separator-->

            -  Therapy for megaloblastic anemia

            <!--list-separator-->

            -  Other defects of nucleoprotein synthesis

                <!--list-separator-->

                -  congenital defects

                <!--list-separator-->

                -  synthetic inhibitors

                <!--list-separator-->

                -  refractory anemias

        <!--list-separator-->

        -  Impaired production--Other

            <!--list-separator-->

            -  Anemia of chronic disease

            <!--list-separator-->

            -  Anemia of renal insufficiency

            <!--list-separator-->

            -  Anemia of liver disease

            <!--list-separator-->

            -  Anemia in endocrine disease

            <!--list-separator-->

            -  Anemia associated with bone marrow infiltration (myelophthisic anemia)

            <!--list-separator-->

            -  Aplastic anemia

            <!--list-separator-->

            -  Pure red cell aplasia

                <!--list-separator-->

                -  Transitory arrest of erythropoiesis

                <!--list-separator-->

                -  Transient erythroblastopenia of childhood

                <!--list-separator-->

                -  Congenital red cell aplasia (Diamond-Blackfan anemia; Congenital hypoplastic anemia)

                <!--list-separator-->

                -  Acquired pure red cell aplasia

            <!--list-separator-->

            -  Sideroblastic anemia

            <!--list-separator-->

            -  Refractory anemia

            <!--list-separator-->

            -  Congenital dyserythropoietic anemias

        <!--list-separator-->

        -  Blood loss anemia

            <!--list-separator-->

            -  Acute posthemorrhagic anemia

            <!--list-separator-->

            -  Chronic posthemorrhagic anemia

        <!--list-separator-->

        -  Hemolysis--general

            <!--list-separator-->

            -  Erythrocyte survival studies

            <!--list-separator-->

            -  Hemoglobin destruction

                <!--list-separator-->

                -  Blood film

                <!--list-separator-->

                -  Bone marrow

        <!--list-separator-->

        -  Hemolysis--membrane disorders

            <!--list-separator-->

            -  Hereditary spherocytosis

            <!--list-separator-->

            -  Hereditary elliptocytosis

        <!--list-separator-->

        -  Hemolysis--hemoglobin disorders

            <!--list-separator-->

            -  Normal hemoglobins

                <!--list-separator-->

                -  Hb A (a2b2)

                <!--list-separator-->

                -  Hb F (a2g2)

                <!--list-separator-->

                -  Hb A2 (a2d2)

                <!--list-separator-->

                -  Embryonic hemoglobins

                <!--list-separator-->

                -  The globin gene clusters

                <!--list-separator-->

                -  Glycosylated hemoglobins

            <!--list-separator-->

            -  Laboratory investigation of hemoglobinopathies and thalassemias

            <!--list-separator-->

            -  Abnormal hemoglobin synthesis

            <!--list-separator-->

            -  Sickling disorders

            <!--list-separator-->

            -  Common alpha chain variants

            <!--list-separator-->

            -  Disorders of hemoglobin function

        <!--list-separator-->

        -  Thalassemias

            <!--list-separator-->

            -  Molecular defects

            <!--list-separator-->

            -  Beta-thalassemias

                <!--list-separator-->

                -  homozygous beta thalassemia (thalassemia major; Cooley's anemia)

                <!--list-separator-->

                -  heterozygous beta-thalassemia (beta thalassemia trait; thalassemia minor; Cooley's trait)

                <!--list-separator-->

                -  beta thalassemia trait with normal hemoglobin a2

                <!--list-separator-->

                -  delta-beta 0 thalassemia

                <!--list-separator-->

                -  delta-beta +: Lepore hemoglobins

            <!--list-separator-->

            -  Hereditary persistence of fetal hemoglobin

            <!--list-separator-->

            -  Alpha thalassemias

                <!--list-separator-->

                -  alpha thalassemia syndromes

                    <!--list-separator-->

                    -  hemoglobin Bart's hydrops fetalis

                    <!--list-separator-->

                    -  hemoglobin H disease

                    <!--list-separator-->

                    -  alpha thalassemia trait: heterozygous alpha 0 thalassemia (\* \* / alpha alpha) or homozygous alpha + thalassemia (\* alpha/ \* alpha)

                    <!--list-separator-->

                    -  silent carrier alpha thalassemia (heterozygous alpha+ thalassemia) (alpha alpha/-alpha)

                    <!--list-separator-->

                    -  hemoglobin constant spring (alphaCS alpha/)

            <!--list-separator-->

            -  Screening and prenatal diagnosis of hemoglobin disorders

        <!--list-separator-->

        -  Hemolysis--metabolic disorders

            <!--list-separator-->

            -  Erythrocyte metabolism

            <!--list-separator-->

            -  Glucose-6-phosphate dehydrogenase deficiency

            <!--list-separator-->

            -  Pyruvate kinase (PK) deficiency

            <!--list-separator-->

            -  Other glycolytic enzyme deficiencies

            <!--list-separator-->

            -  Pyrimidine-5'-nucleotidase deficiency

        <!--list-separator-->

        -  Hemolysis--acquired; extrinsic

            <!--list-separator-->

            -  Chemical agents

            <!--list-separator-->

            -  Physical agents

            <!--list-separator-->

            -  Infectious agents

            <!--list-separator-->

            -  Immune hemolytic anemias

        <!--list-separator-->

        -  Laboratory investigations of anemia

            <!--list-separator-->

            -  Macrocytic anemia (increased MCV)

            <!--list-separator-->

            -  Microcytic and hypochromic anemias (decreased MCV and MCH)

                <!--list-separator-->

                -  iron deficiency anemias

                    <!--list-separator-->

                    -  low iron low TIBC

                <!--list-separator-->

                -  anemia of chronic disease

                    <!--list-separator-->

                    -  low iron normal TIBC

                <!--list-separator-->

                -  thalassemia

                    <!--list-separator-->

                    -  normal to elevated iron with hypochromic anemia and basophilic stippling

                <!--list-separator-->

                -  sideroblastic anemia

            <!--list-separator-->

            -  Normocytic and normochromic anemias (normal MCV)

                <!--list-separator-->

                -  optimal marrow response: reticulocyte production index greater than two

                    <!--list-separator-->

                    -  direct antiglobulin (Coombs) test

                <!--list-separator-->

                -  inadequate marrow response: reticulocyte production index less than two

    <!--list-separator-->

    -  32.2 Polycythemia

        <!--list-separator-->

        -  Relative polycythemia

        <!--list-separator-->

        -  Absolute polycythemia

        <!--list-separator-->

        -  Measurement of erythrocyte and plasma volume

    <!--list-separator-->

    -  32.3 Porphyrias

        <!--list-separator-->

        -  Physiology

        <!--list-separator-->

        -  Approach to the porphyrias

        <!--list-separator-->

        -  Clinical porphyrias and their biochemical basis

        <!--list-separator-->

        -  Analytic techniques

<!--list-separator-->

-  33. Leukocytic disorders (606-658)

    <!--list-separator-->

    -  33.1 Leukocytes

    <!--list-separator-->

    -  33.2 Nonneoplastic disorders

        <!--list-separator-->

        -  Granulocytic and monocytic disorders

        <!--list-separator-->

        -  Lymphocytic and plasmacytic disorders

        <!--list-separator-->

        -  Leukemoid reactions

    <!--list-separator-->

    -  33.3 Neoplastic disorders primarily involving leukocytes

        <!--list-separator-->

        -  Overview of hematopoietic neoplasms

            <!--list-separator-->

            -  CML t(9;22)(q34;q11) BCR/ABL translocation targeted by imatinib / Gleevec

            <!--list-separator-->

            -  promyelocytic leukemia t(15;17)(q22;q12) PML/RARA abnormal retinoic acid receptor responds to all-trans retinoic acid

        <!--list-separator-->

        -  Chronic myeloproliferative disorders

            <!--list-separator-->

            -  Introduction

                <!--list-separator-->

                -  Includes clonal proliferations of pluripotent stem cells that can differentiate along granulocytic, erythroid, and megakaryocytic lines

                <!--list-separator-->

                -  The chronic course may terminate as acute leukemia, myelofibrosis, or coagulopathy

            <!--list-separator-->

            -  Chronic myelogenous leukemia

                <!--list-separator-->

                -  +/\* BCR/ABL1

                <!--list-separator-->

                -  Clinical features

                    <!--list-separator-->

                    -  Young and middle aged; >50

                    <!--list-separator-->

                    -  Anemia, weight loss, splenomegaly, fever and night sweats

                <!--list-separator-->

                -  Laboratory features

                    <!--list-separator-->

                    -  Blood

                        <!--list-separator-->

                        -  increased leukocyte count (usually >5e9/L , possibly >30e9/L )

                        <!--list-separator-->

                        -  normocytic anemia

                    <!--list-separator-->

                    -  Marrow

                        <!--list-separator-->

                        -  markedly hypercellular due to granulocytic proliferation

                        <!--list-separator-->

                        -  failure to aspirate due to cellular density and increased reticulin

                        <!--list-separator-->

                        -  blue pigment laden macrophages

                    <!--list-separator-->

                    -  Neutrophil alkaline phosphatase

                        <!--list-separator-->

                        -  greatly reduced or absent in more than 90% of patients

                        <!--list-separator-->

                        -  this is in contrast to elevations seen in PV, IMF, and leukemoid reactions

                    <!--list-separator-->

                    -  Cytogenetic abnormalities

                        <!--list-separator-->

                        -  t(9;22)(q34;q11) in more than 95%

                            <!--list-separator-->

                            -  the BCR-ABL1 fusion results in a novel RNA transcript and associated growth factor with tyrosine kinase activity higher than that of the normal p145 protein encoded by the ABL1 gene

                        <!--list-separator-->

                        -  Major and minor breakpoint regions of BCR

                            <!--list-separator-->

                            -  M-BCR --> p210

                            <!--list-separator-->

                            -  mu region --> p230

                            <!--list-separator-->

                            -  m-BCR --> p190 --> usually associated with ALL

                    <!--list-separator-->

                    -  Other findings

                        <!--list-separator-->

                        -  Serum cobalamin and transcobalamin are usually increased as a result of increased transcobalamin I reflecting the size of the total blood granulocyte pool

                        <!--list-separator-->

                        -  Lysozyme (muramidase) is also increased

                <!--list-separator-->

                -  Course

                    <!--list-separator-->

                    -  Untreated patients or those who fail treatment progress to a more aggressive or accelerated phase characterized by features of progressive myeloproliferation

                    <!--list-separator-->

                    -  Blast phase is a progression to acute leukemia defined by >20% blasts in the blood or BM which is myeloid lineage in >70% of cases. In approximately 1/3 of cases ALL mostly of precursor B-lineage appears.

            <!--list-separator-->

            -  Chronic neutrophilic leukemia

            <!--list-separator-->

            -  Polycythemia vera

                <!--list-separator-->

                -  JAK2 V617F

            <!--list-separator-->

            -  Primary myelofibrosis

            <!--list-separator-->

            -  Essential thrombocythemia

            <!--list-separator-->

            -  MPN with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1

            <!--list-separator-->

            -  Chronic eosinophilic leukemia

            <!--list-separator-->

            -  Mastocytosis

            <!--list-separator-->

            -  Myelodysplastic and myelodysplastic/myeloproliferative neoplasms

            <!--list-separator-->

            -  Myelodysplastic/myeloproliferative disease, unclassifiable

            <!--list-separator-->

            -  Myelodysplastic syndromes

        <!--list-separator-->

        -  Acute myeloid leukemia

            <!--list-separator-->

            -  Acute leukemia with recurrent genetic abnormalities

                <!--list-separator-->

                -  AML with balanced translocations/inversions

                    <!--list-separator-->

                    -  AML with t(8;21)(q22;q22) RUNX1-RUNX1T1

                    <!--list-separator-->

                    -  AML with inv(16)(p13q22) or t(16;16)(p13.1;q22), CBF beta/MYH11

                    <!--list-separator-->

                    -  Acute promyelocytic leukemia with t(15;17)(q22;q12) PML/RARA, and variants

                    <!--list-separator-->

                    -  AML with t(9;11)(p22;q23); MLLT3-MLL

                    <!--list-separator-->

                    -  AML with t(6;9)(p23;q34); DEK-NUP214

                    <!--list-separator-->

                    -  AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1

                    <!--list-separator-->

                    -  AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1

                <!--list-separator-->

                -  AML with gene mutations

                    <!--list-separator-->

                    -  AML with FLT3 mutation

                    <!--list-separator-->

                    -  AML with NPM1 mutation

                    <!--list-separator-->

                    -  AML with CEBPA mutation

            <!--list-separator-->

            -  Acute myeloid leukemia with myelodysplasia-related changes

            <!--list-separator-->

            -  Acute myeloid leukemia, NOS

            <!--list-separator-->

            -  Myeloid proliferations related to Down syndrome

            <!--list-separator-->

            -  Acute leukemias of ambiguous lineage

        <!--list-separator-->

        -  Precursor lymphoid neoplasms

            <!--list-separator-->

            -  B lymphoblastic leukemia/lymphoma

            <!--list-separator-->

            -  B lymphoblastic leukemia/lymphoma, NOS

        <!--list-separator-->

        -  Mature B cell neoplasms

            <!--list-separator-->

            -  Monoclonal B cell lymphocytosis

            <!--list-separator-->

            -  Chronic lymphocytic leukemia/Small lymphocytic lymphoma

                <!--list-separator-->

                -  M>F over 60 years

                <!--list-separator-->

                -  Fatigue, lymphadenopathy WBC > 5e3/uL, anemia, thrombocytopenia

            <!--list-separator-->

            -  B cell prolymphocytic leukemia

            <!--list-separator-->

            -  Splenic marginal zone lymphoma

            <!--list-separator-->

            -  Hairy cell leukemia

            <!--list-separator-->

            -  Splenic B cell lymphoma/leukemia, unclassifiable

            <!--list-separator-->

            -  Hairy cell leukemia variant

            <!--list-separator-->

            -  Lymphoplasmacytic lymphoma

            <!--list-separator-->

            -  Heavy chain diseases

            <!--list-separator-->

            -  Plasma cell neoplasms

                <!--list-separator-->

                -  MGUS

                <!--list-separator-->

                -  plasma cell myeloma

            <!--list-separator-->

            -  Monoclonal immunoglobulin deposition diseases

            <!--list-separator-->

            -  Extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue

            <!--list-separator-->

            -  Nodal marginal zone lymphoma

            <!--list-separator-->

            -  Follicular lymphoma

            <!--list-separator-->

            -  Mantle cell lymphoma

            <!--list-separator-->

            -  Diffuse large B cell lymphoma, NOS

            <!--list-separator-->

            -  Lymphomatoid granulomatosis

            <!--list-separator-->

            -  Primary mediastinal thymic large B cell lymphoma

            <!--list-separator-->

            -  Intravascular large B cell lymphoma

            <!--list-separator-->

            -  ALK-positive large B cell lymphoma

            <!--list-separator-->

            -  Plasmablastic lymphoma

            <!--list-separator-->

            -  Large B cell lymphoma arising in HHV8-associated multicentric Castleman's disease

            <!--list-separator-->

            -  Primary effusion lymphoma

            <!--list-separator-->

            -  Burkitt lymphoma

            <!--list-separator-->

            -  B cell lymphoma unclassifiable with features intermediate between DLBCL and Burkitt lymphoma

            <!--list-separator-->

            -  B cell lymphoma unclassifiable with features intermediate between DLBCL and classical Hodgkin lymphoma

        <!--list-separator-->

        -  Mature T cell and natural killer cell neoplasms

            <!--list-separator-->

            -  T-prolymphocytic leukemia

            <!--list-separator-->

            -  Large granular lymphocyte leukemia

            <!--list-separator-->

            -  Chronic-lymphoproliferative disorders of NK cells

            <!--list-separator-->

            -  Aggressive NK cell leukemia

            <!--list-separator-->

            -  EBV-positive T cell lymphoproliferative disorders of childhood

            <!--list-separator-->

            -  Adult T cell leukemia-lymphoma

            <!--list-separator-->

            -  Extranodal NK/T cell lymphoma, Nasal type

            <!--list-separator-->

            -  Enteropathy-associated T cell lymphoma

            <!--list-separator-->

            -  Hepatosplenic T cell lymphoma

            <!--list-separator-->

            -  Subcutaneous panniculitis-like T cell lymphoma

            <!--list-separator-->

            -  Mycosis fungoides and Sezary syndrome

            <!--list-separator-->

            -  Primary cutaneous CD30-positive T cell lymphoproliferative disorder

            <!--list-separator-->

            -  Primary cutaneous gamma delta T cell lymphoma

            <!--list-separator-->

            -  Angioimmunoblastic T cell lymphoma

            <!--list-separator-->

            -  Peripheral T/NK cell lymphoma, unspecified

            <!--list-separator-->

            -  Anaplastic large cell lymphoma

            <!--list-separator-->

            -  Anaplastic large cell lymphoma ALK negative

        <!--list-separator-->

        -  Hodgkin lymphoma

            <!--list-separator-->

            -  Classical hodgkin lymphoma

                <!--list-separator-->

                -  nodular sclerosis

                <!--list-separator-->

                -  mixed cellularity

                <!--list-separator-->

                -  lymphocyte depletion

            <!--list-separator-->

            -  Nodular lymphocyte-predominant HL

            <!--list-separator-->

            -  Nodular lymphocyte-rich classical HL

        <!--list-separator-->

        -  Immunodeficiency-associated lymphoproliferative disorders

            <!--list-separator-->

            -  HIV-associated lymphomas

            <!--list-separator-->

            -  Posttransplant lymphoproliferative disorders

        <!--list-separator-->

        -  Histiocytic and dendritic cell neoplasms

            <!--list-separator-->

            -  Hemophagocytic syndromes, or hemophagocytic lymphohistiocytosis (HLH)

            <!--list-separator-->

            -  Langerhans cell histiocytosis

            <!--list-separator-->

            -  Interdigitating dendritic cell sarcoma/tumor

            <!--list-separator-->

            -  Follicular dendritic cell sarcoma/tumor

            <!--list-separator-->

            -  Dendritic cell sarcoma, not otherwise specified

<!--list-separator-->

-  34. The flow cytometric evaluation of hematopoietic neoplasia (659-679)

    <!--list-separator-->

    -

<!--list-separator-->

-  35. Immunohematology (680-734)


### transfusion medicine {#transfusion-medicine}

<!--list-separator-->

-  36. Transfusion medicine

<!--list-separator-->

-  37. Hemapheresis

<!--list-separator-->

-  38. Tissue banking and progenitor cells


## Part 5: Hemostasis and Thrombosis {#part-5-hemostasis-and-thrombosis}


### coagulation {#coagulation}

<!--list-separator-->

-  39. Coagulation and fibrinolysis

<!--list-separator-->

-  40. Platelet disorders and von Willebrand disease

<!--list-separator-->

-  41. Laboratory approach to thrombotic risk

<!--list-separator-->

-  42. Antithrombotic therapy


## Part 6: Immunology and immunopathoogy {#part-6-immunology-and-immunopathoogy}


### 43. Overview of the immune system and immunologic disorders {#43-dot-overview-of-the-immune-system-and-immunologic-disorders}


### 44. Immunoassays and immunochemistry {#44-dot-immunoassays-and-immunochemistry}


### 45. Laboratory evaluation of the cellular immune system {#45-dot-laboratory-evaluation-of-the-cellular-immune-system}


### 46. Laboratory evaluation of immunoglobulin function and humoral immunity {#46-dot-laboratory-evaluation-of-immunoglobulin-function-and-humoral-immunity}


### 47. Mediators of inflammation: complement, cytokines, and adhesion molecules {#47-dot-mediators-of-inflammation-complement-cytokines-and-adhesion-molecules}


### 48. Mediators of inflammation: cytokines and adhesion molecules {#48-dot-mediators-of-inflammation-cytokines-and-adhesion-molecules}


### 49. Human leukocyte antigen: the major histocompatibility complex of man {#49-dot-human-leukocyte-antigen-the-major-histocompatibility-complex-of-man}


### 50. The major histocompatibility complex and disease {#50-dot-the-major-histocompatibility-complex-and-disease}


### 51. Immunodeficiency disorders {#51-dot-immunodeficiency-disorders}


### 52. Clinical and laboratory evaluation of systemic rheumatic diseases {#52-dot-clinical-and-laboratory-evaluation-of-systemic-rheumatic-diseases}


### 53. Vasculitis {#53-dot-vasculitis}


### 54. Organ-specific autoimmune diseases {#54-dot-organ-specific-autoimmune-diseases}


### 55. Allergic diseases {#55-dot-allergic-diseases}


## Part 8: Molecular pathology {#part-8-molecular-pathology}


### 65. Introduction to molecular pathology {#65-dot-introduction-to-molecular-pathology}


### 66. Molecular diagnostics: basic principles and techniques {#66-dot-molecular-diagnostics-basic-principles-and-techniques}


### 67. Polymerase chain reaction and other nucleic acid amplification technologies {#67-dot-polymerase-chain-reaction-and-other-nucleic-acid-amplification-technologies}


### 68. Hybridization array technologies {#68-dot-hybridization-array-technologies}


### 69. Applications of cytogenetics in modern pathology [progress indicators]({{< relref "progress_indicators" >}}) {#69-dot-applications-of-cytogenetics-in-modern-pathology-progress-indicators--progress-indicators-dot-md}

<!--list-separator-->

-  Definitions

<!--list-separator-->

-  Cytogenetics

    <!--list-separator-->

    -  Chromosomes

        <!--list-separator-->

        -  Chromosome structure

        <!--list-separator-->

        -  Cell culture

            <!--list-separator-->

            -  specimens

            <!--list-separator-->

            -  cell culture technique

        <!--list-separator-->

        -  Staining

        <!--list-separator-->

        -  Karyotype analysis

            <!--list-separator-->

            -  computer-assisted imaging

        <!--list-separator-->

        -  Fluorescence in situ hybridization

            <!--list-separator-->

            -  technique

            <!--list-separator-->

            -  multicolor FISH

        <!--list-separator-->

        -  Microarray technology

    <!--list-separator-->

    -  Chromosome abnormalities

        <!--list-separator-->

        -  numerical abnormalities

            <!--list-separator-->

            -  euploidy

            <!--list-separator-->

            -  aneuploidy

        <!--list-separator-->

        -  structural chromosome abnormalities

        <!--list-separator-->

        -  nomenclature

<!--list-separator-->

-  Clinical applications

    <!--list-separator-->

    -  Constitutional cytogenetics

        <!--list-separator-->

        -  prenatal

        <!--list-separator-->

        -  postnatal

        <!--list-separator-->

        -  childhood and adult

    <!--list-separator-->

    -  Cancer genetics

    <!--list-separator-->

    -  Cytogenetic disorders

        <!--list-separator-->

        -  Chromosomal Aneuploidy Syndromes

            <!--list-separator-->

            -  Autosomal Aneuploidies

            <!--list-separator-->

            -  Sex Chromosome Aneuploidies

        <!--list-separator-->

        -  Other Sex Chromosome Abnormalities

        <!--list-separator-->

        -  Structural Chromosome Anomalies

        <!--list-separator-->

        -  Microdeletion Syndromes and Contiguous Gene Syndromes

    <!--list-separator-->

    -  Other cytogenetic phenomena

        <!--list-separator-->

        -  Fragile X Syndrome

        <!--list-separator-->

        -  Breakage Syndromes

            <!--list-separator-->

            -  See list in table 69-6

<!--list-separator-->

-  Summary


### 70. Establishing a molecular diagnostics laboratory {#70-dot-establishing-a-molecular-diagnostics-laboratory}


### 71. Molecular diagnosis of genetic diseases {#71-dot-molecular-diagnosis-of-genetic-diseases}


### 72. Identity analysis: use of DNA analysis in parentage, forensic, and missing persons testing {#72-dot-identity-analysis-use-of-dna-analysis-in-parentage-forensic-and-missing-persons-testing}


### 73. Pharmacogenomics and personalized medicine {#73-dot-pharmacogenomics-and-personalized-medicine}


## Part 9: Molecular pathology {#part-9-molecular-pathology}


### 74. Diagnosis and management of cancer using serologic and other body fluid markers {#74-dot-diagnosis-and-management-of-cancer-using-serologic-and-other-body-fluid-markers}


### 75. Oncoproteins and early tumor detection {#75-dot-oncoproteins-and-early-tumor-detection}


### 76. Molecular diagnosis of hematopoietic neoplasms [progress indicators]({{< relref "progress_indicators" >}}) {#76-dot-molecular-diagnosis-of-hematopoietic-neoplasms-progress-indicators--progress-indicators-dot-md}

<!--list-separator-->

-  Role of clinical molecular diagnostics in hematologic cancers

<!--list-separator-->

-  Molecular diagnosis of leukemias

    <!--list-separator-->

    -  Gene fusion concept in leukemia and the basis for reverse-transcription polymerase chain reaction analysis

    <!--list-separator-->

    -  Acute myeloid leukemias

        <!--list-separator-->

        -  Acute Promyelocytic Leukemia: t(15;17) (q22;q21)/PML-RARA Abnormality

        <!--list-separator-->

        -  Core Binding Factor–Related Acute Myeloid Leukemias: t(8;21)(q22;q22)/RUNX1-RUNX1T1 and Inv(16)(p13q22) or t(16;16)(p13;q22)/CBFB-MYH11 Abnormalities

        <!--list-separator-->

        -  Acute Myeloid Leukemia with Other Translocations

            <!--list-separator-->

            -  AML with 11q23/MLL

            <!--list-separator-->

            -  AML with t(6;9)(p23;q34)/DEK-NUP214

            <!--list-separator-->

            -  AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)/RPN1-EVI1

            <!--list-separator-->

            -  AML (Megakaryoblastic) with t(1;22)(p13;q13)/RBM15-MKL1

            <!--list-separator-->

            -  Acute Myeloid Leukemias with FLT3, NPM1, and CEBPA Gene Mutations

        <!--list-separator-->

        -  FLT3 Mutations in Acute Myeloid Leukemia

        <!--list-separator-->

        -  NPM1 Mutations in Acute Myeloid Leukemia

        <!--list-separator-->

        -  CEBPA Mutations in Acute Myeloid Leukemia

        <!--list-separator-->

        -  Other Gene Mutations in Acute Myeloid Leukemias

            <!--list-separator-->

            -  Mutations involving many other genes, including WT1 (see below), MLL, TET2, JAK2, IDH1/IDH2, EZH2, PLK1, NRAS, and KRAS, have been associated with prognostic or biologic importance in AML.

    <!--list-separator-->

    -  Acute lymphoblastic leukemia/lymphoma--B and T cell lineage

        <!--list-separator-->

        -  B Cell Lymphoblastic Leukemia/Lymphoma (Precursor B Cell Acute Lymphoblastic Leukemia, B-ALL)

        <!--list-separator-->

        -  Major Translocation Fusion Gene Abnormalities in B Cell ALL

            <!--list-separator-->

            -  t(9;22)(q34;q11.2)/1BCR-ABL1 is found in approximately 3% to 4% of childhood B-lineage ALL, but it occurs in 20% to 25% of adult B-ALL

        <!--list-separator-->

        -  Prenatal Origins of Childhood Leukemias

        <!--list-separator-->

        -  BCR-ABL1–Like B-Acute Lymphoblastic Leukemia

        <!--list-separator-->

        -  T Cell Lymphoblastic Leukemia/Lymphoma

    <!--list-separator-->

    -  Molecular diagnosis of myeloproliferative neoplasms

        <!--list-separator-->

        -  Chronic Myelogenous Leukemia with t(9;22) (q34;q11)/BCR-ABL1 Positive

        <!--list-separator-->

        -  Ph-Negative Myeloproliferative Neoplasms: Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis—JAK2, MPL Gene, and CALR Mutations

        <!--list-separator-->

        -  Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia with CSF3R Gene Mutation

        <!--list-separator-->

        -  Mastocytosis and the KIT D816V Gene Mutation

<!--list-separator-->

-  Neoplastic disorders associated with eosinophilia

<!--list-separator-->

-  Molecular diagnosis of non-hodgkin lymphomas

    <!--list-separator-->

    -  Rationale for molecular genetic analysis in the lymphoid disorders

    <!--list-separator-->

    -  Antigen receptor gene rearrangements for clonality determination

        <!--list-separator-->

        -  Mechanism of Antigen Receptor Gene Rearrangements

        <!--list-separator-->

        -  Techniques to Detect Antigen Receptor Gene Rearrangements: Southern Blot Hybridization

            <!--list-separator-->

            -  Advantages and Shortcomings of Southern Blot Hybridization and Polymerase Chain Reaction for Lymphoid Clonality Assessment

    <!--list-separator-->

    -  Molecular detection and significance of common lymphoma-associated chromosomal translocations

        <!--list-separator-->

        -  t(14;18)/BCL2-IGH Abnormality in Follicular and Diffuse Large B Cell Lymphomas

        <!--list-separator-->

        -  t(11;14)/CCND1-IGH Abnormality in Mantle Cell Lymphoma

        <!--list-separator-->

        -  MALT1, BCL10, and FOXP1 Gene Abnormalities in Extranodal Marginal Zone B Cell Lymphomas

        <!--list-separator-->

        -  Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Molecular and Cytogenetic Prognostic Markers

        <!--list-separator-->

        -  Diffuse Large B Cell Lymphomas: Role of BCL6 and MYC Gene Abnormalities and Classification Based on Gene Expression Profiling

        <!--list-separator-->

        -  MYC Gene Translocations in Burkitt Lymphomas and “High-Grade” B Cell Lymphomas, Unclassifiable

        <!--list-separator-->

        -  MYD88 Mutation in Non-Hodgkin B Cell Lymphoma

        <!--list-separator-->

        -  ALK Gene Abnormalities in Anaplastic Large Cell Lymphomas

        <!--list-separator-->

        -  TCL1A Gene Abnormalities in T Cell

            Prolymphocytic Leukemia

        <!--list-separator-->

        -  The Implication of Next Gene Sequencing (NGS) in Hematolymphoid Lesions

<!--list-separator-->

-  Emerging technologies impacting molecular diagnosis and prognosis prediction in hematolymphoid neoplasia


### 77. Molecular genetic pathology of solid tumors {#77-dot-molecular-genetic-pathology-of-solid-tumors}


### 78. High-throughput genomic and proteomic technologies in the postgenomic era {#78-dot-high-throughput-genomic-and-proteomic-technologies-in-the-postgenomic-era}
